The WHO has released its first global guideline on GLP-1 therapies for obesity — finally treating obesity as a chronic disease requiring long-term, integrated care. It marks a pivotal shift: medications are necessary but not enough, behavioural support must be sustained, and real-world data will shape the future of obesity care globally.

Awareness of GLP-1 medications is rising online, but it’s far from universal. In many countries, most people don’t even know these treatments exist—making care feel out of reach. nymble closes that gap with clear, clinically grounded support delivered through SMS and WhatsApp, in people’s own language. No apps, no barriers—just trustworthy guidance that meets people where they are.

For decades, obesity care has focused on biology—genes, hormones, and lab values—while overlooking the behaviours that drive real outcomes. What if the strongest predictors of success aren’t in our DNA, but in our daily decisions? At nymble, we’re using conversational and behavioural data to uncover new “digital phenotypes” that predict treatment response and guide more personalized, compassionate obesity care.